Targeting Kindlin-2 in adipocytes increases bone mass through inhibiting FAS/PPAR<i>γ</i>/FABP4 signaling in mice.

Authors:
Tang W; Ding Z; Gao H; Yan Q; Liu J and 7 more

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.07.001

PMCID:
PMC10638509

PMID:
37969743

Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest The corresponding authors Huiling Cao and Guixing Ma have filed a patent application (202210877899. X) for the treatment of OP. The other authors declare no conflicts of interests."

Evidence found in paper:

"We acknowledge the assistance of Core Research Facilities of Southern University of Science and Technology. Support of this work partially came from 10.13039/100014717National Natural Science Foundation of China Grants (82022047 and 81972100), the 10.13039/501100012166National Key Research and Development Program of China Grants (2019YFA0906001), Guangdong Provincial Science and Technology Innovation Council Grant (2017B030301018, China)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025